|
|
 |
| MACS® GMP Recombinant Human TNF-α |
|
| Overview |
Tumor necrosis factor alpha (TNF-α) has a broad spectrum of biological activities. In addition to its central role in inflammation TNF-α is involved in regulating apoptotic cell death, cellular proliferation, and differentiation.
MACS GMP Recombinant Human TNF-α is designed for ex vivo cell culture processing. No animal- or human-derived materials were used for manufacture of this product. The product is lyophilized without carrier protein or preservatives. |
| Details |
Background information
TNF-α is mainly produced by activated monocytes and macrophages, but also by a broad variety of other cell types including lymphoid cells, mast cells, endothelial cells, fibroblasts, and astrocytes. Beside its primary role in immune regulation, TNF-α promotes angiogenesis, bone resorption, and thrombotic processes.
Applications
MACS GMP Recombinant Human TNF-α can be used for a variety of applications, including the ex vivo generation of human dendritic cells from enriched CD14+ monocyte populations.1-3
Quality statement
MACS GMP Products are manufactured and tested under a certified ISO 9001 quality system and in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
A lot-specific certificate of analysis is provided, confirming identity, molecular mass, specific activity, sterility, purity, endotoxin content, and host-cell DNA content. |
| Disclaimer |
| MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. |
| | |
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| MACS GMP Recombinant Human TNF-α |
| Availability: Worldwide (1) |
| Source: E. coli |
- 25 μg
Download datasheet
170-076-103
|
| (1) For availability in your country please contact your local representative. |
|
| References |
| 1. Bender et al. (1996) J. Immunol. Methods 196: 121–135. |
| 2. Romani et al. (1996) J. Immunol. Methods 196: 137–151. |
| 3. Jonuleit et al. (1997) Eur. J. Immunol. 27: 3135–3142. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
